REYKJAVIK, Iceland, Dec. 5 /PRNewswire-FirstCall/ -. deCODE genetics today announced that it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission for the issuance and sale from time to time of debt and equity securities either individually or in units, in one or more offerings, with a total value of up to $100 million. Any such securities will in each case be offered pursuant to a prospectus supplement that will describe the particular terms of the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification of the securities under the securities laws of any such state.
A written prospectus, when available, meeting the requirements of Section 10 of the Securities Act of 1933, may be obtained by writing to Kristin Asgeirsdottir, deCODE genetics, Inc., Sturlugata 8, 101 Reykjavik, Iceland.
About deCODE
deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs for common diseases. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at http://www.decode.com.
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE’s filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
Contact: deCODE genetics Edward Farmer Joy Bessenger +1 (212) 343 2819 +1 (212) 481-3891 info@decode.isir@decode.is
deCODE genetics
CONTACT: Edward Farmer, +1-212-343-2819, info@decode.is, or Joy Bessenger,+1-212-481-3891, ir@decode.is, both of deCODE genetics
Web site: http://www.decode.com/
